Menopausal Syndrome Clinical Trial
Official title:
Effect and Safety of Electroacupuncture for Symptoms of Menopausal Transition —a Multicenter Randomized Controlled Trial
NCT number | NCT01849172 |
Other study ID # | BAI24B01 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | June 2013 |
Est. completion date | December 2016 |
Verified date | March 2019 |
Source | Guang'anmen Hospital of China Academy of Chinese Medical Sciences |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The primary object is to evaluate the efficacy and safety of electroacupuncture for symptoms of women during menopausal transition .
Status | Completed |
Enrollment | 360 |
Est. completion date | December 2016 |
Est. primary completion date | December 2015 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 40 Years to 55 Years |
Eligibility |
Inclusion Criteria: 1. Cycle irregularity (periods occur 7 days or over earlier or later ) in the past 12 months (early menopausal transition); subjects with the last menstruation at least 2 but no longer than 12 months in the past 12 months (late menopausal transition). 2. Menopausal transition symptoms such as hot flushes, sweating, sleep disturbance, migraine, anxiety, vaginal dryness and sexual problems. 3. 40 to 55 years old. 4. Volunteer to join in the trial and sign the informed consent. Patients conformed with the 4 items at the same time will be included. - Exclusion Criteria: 1. Regular cycles during the past 3 months before enrollment. 2. use of estrogen, SSRIs, soybean isoflavone, progestin, vitamin E or black sesame in the past 4 weeks. 3. Patients with ovarian cyst, uterine myoma (diameter=4cm) or after hysterectomy/ ovariectomy. 4. Patients with radiochemotherapy history or undergoing radiochemotherapy. 5. Cryptogenic vaginal bleeding 6. Coagulation disorder or use of anticoagulants like warfarin and heparin sodium. 7. Existing skin diseases like eczema or psoriasis. 8. Severe hepatic/renal insufficiency. 9. Insufficiently controlled hypertension, diabetes or thyroid diseases. 10. Existing diabetic neuropathy, malignant tumor and psychiatric disorders. 11. Wish to become pregnant or is pregnant or breast-feeding. 12. Regular use of sedative or anxiolytic. 13. Smoking or alcohol intake. 14. Subjects with mandatory indication for HT (e.g. postsurgical menopause or active osteoporosis). 15. With cardiac pacemaker or artificial joint. |
Country | Name | City | State |
---|---|---|---|
China | Guangan'men Hospital | Beijing |
Lead Sponsor | Collaborator |
---|---|
Guang'anmen Hospital of China Academy of Chinese Medical Sciences | Ministry of Science and Technology of the People´s Republic of China |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change From Baseline in Menopause Rating Scale Total Score | The change in menopause rating scale (MRS) total score compared with baseline at week 8 equals MRS total score at week 8 minus MRS total score at baseline. MRS is a self-report questionnaire for evaluating the severity of menopausal symptoms in women, which contains 11 items. Each of the 11 symptoms contained a scoring scale from "0" (no complaints) to "4" (very severe symptoms). The total score will be calculated as the all items ranging from 0 to 44, with higher scores indicating worse symptoms. The MRS including 3 dimensions: psychological, somatic-vegetative, and urogenital. |
at baseline and week 8 | |
Secondary | Change From Baseline in Menopause Rating Scale Total Score | The change in Menopause Rating Scale (MRS)total score compared with baseline at weeks 4, 20 and 32 equals MRS total score at weeks 4, 20 and 32 minus MRS total score at baseline,respectively. MRS is a self-report questionnaire for evaluating the severity of menopausal symptoms in women, which contains 11 items. Each of the 11 symptoms contained a scoring scale from "0" (no complaints) to "4" (very severe symptoms). The total score will be calculated as the all items ranging from 0 to 44, with higher scores indicating worse symptoms. The MRS including 3 dimensions: psychological, somatic-vegetative, and urogenital. |
at baseline,and weeks 4, 20 and 32 | |
Secondary | Change From Baseline in Somatic-vegetative Domain of Menopause Rating Scale | The change from baseline in somatic-vegetative domain of Menopause Rating Scale(MRS) at weeks 4, 8, 20 and 32 equals the somatic-vegetative domain of MRS at weeks 4, 8, 20 and 32 minus the somatic-vegetative domain of MRS at baseline, respectively. The somatic-vegetative domain contains 4 items (items 1-3 and 11). Each of the item scores ranges from 0 to 4. The somatic-vegetative domain score will be calculated as the all somatic-vegetative items ranging from 0 to 16, with higher scores indicating worse symptoms. |
at baseline, and weeks 4, 8, 20 and 32 | |
Secondary | Change From Baseline in Psychological Domain of Menopause Rating Scale | The change from baseline in psychological domain of Menopause Rating Scale(MRS) at weeks 4, 8, 20 and 32 equals the psychological domain of MRS at weeks 4, 8, 20 and 32 minus the psychological domain of MRS at baseline, respectively. The psychological domain contains 4 items (items 4-7). Each of the item scores ranges from 0 to 4. The psychological domain score will be calculated as the all psychological items ranging from 0 to 16, with higher scores indicating worse symptoms. |
at baseline, and weeks 4, 8, 20 and 32 | |
Secondary | Change From Baseline in Urogenital Domain of Menopause Rating Scale | The change from baseline in urogenital domain of Menopause Rating Scale(MRS) at weeks 4, 8, 20 and 32 equals the urogenital domain of MRS at weeks 4, 8, 20 and 32 minus the urogenital domain of MRS at baseline, respectively. The urogenital domain contains 3 items (items 8-10). Each of the item scores ranges from 0 to 4. The psychological domain score will be calculated as the all urogenital items ranging from 0 to 12, with higher scores indicating worse symptoms. |
at baseline, and weeks 4, 8, 20 and 32 | |
Secondary | Change From Baseline in Mean 24-h Hot Flash Score | The 24-h hot flash score was daily hot flash episodes multiplied by the corresponding severities. The change from baseline in mean 24-h HF score at weeks 4, 8, 20 and 32 equals the mean 24-h HF score at weeks 4 , 8, 20 and 32 minus the mean 24-h HF score at baseline, respectively. Hot flashes score consisted the number and the degree of hot flashes. The hot flashes score is the sum of the scores of all the hot flashes occurring in a whole day, with a higher score indicating worse symptoms. A 3-point rating scale allows the women to describe the perceived severity of hot flash. 1 point = mild hot flash, 2 point = moderate hot flash, 3 point = severe hot flash. |
at baseline, and weeks 4, 8, 20 and 32 | |
Secondary | Change From Baseline in Menopause-Specific Quality of Life Questionnaire Total Score | The change from baseline in Menopause-Specific Quality of Life Questionnaire (MENQOL) total score at weeks 4, 8, 20 and 32 equals the MENQOL total score at weeks 4, 8, 20 and 32 minus the MENQOL score at baseline, respectively. It composed of 29 items and was divided into four domains: vasomotor (items 1-3), psychosocial (items 4-10), physical (items 11-26), and sexual (items 27-29). Each of the item scores ranges from 0 to 6. The total score will be calculated as the all items ranging from 0 to 174, with lower scores indicating a better quality of life. |
at baseline, and weeks 4, 8, 20 and 32 | |
Secondary | Change From Baseline in the Vasomotor Domain of Menopause-Specific Quality of Life Questionnaire | The change from baseline in the vasomotor domain of Menopause-Specific Quality of Life Questionnaire (MENQOL) at weeks 4, 8, 20 and 32 equals the vasomotor domain of MENQOL at weeks 4, 8, 20 and 32 minus the vasomotor domain of MENQOL at baseline, respectively. The vasomotor domain contains 3 items (items 1-3). Each of the item scores ranges from 0 to 6. The vasomotor domain score will be calculated as the all vasomotor items ranging from 0 to 18, with lower scores indicating a better quality of life. |
at baseline, and weeks 4, 8, 20 and 32 | |
Secondary | Change From Baseline in the Psychosocial Domain of Menopause-Specific Quality of Life Questionnaire | The change from baseline in the psychosocial domain of Menopause-Specific Quality of Life Questionnaire (MENQOL) at weeks 4, 8, 20 and 32 equals the psychosocial domain of MENQOL at weeks 4, 8, 20 and 32 minus the psychosocial domain of MENQOL at baseline, respectively. The psychosocial domain contains 7 items (items 4-10). Each of the item scores ranges from 0 to 6. The vasomotor domain score will be calculated as the all psychosocial items ranging from 0 to 42, with lower scores indicating a better quality of life. |
at baseline, and weeks 4, 8, 20 and 32 | |
Secondary | Change From Baseline in the Physical Domain of Menopause-Specific Quality of Life Questionnaire | The change from baseline in the physical domain of Menopause-Specific Quality of Life Questionnaire (MENQOL) at weeks 4, 8, 20 and 32 equals the physical domain of MENQOL at weeks 4, 8, 20 and 32 minus the physical domain of MENQOL at baseline, respectively. The physical domain contains 16 items (items 11-26). Each of the item scores ranges from 0 to 6. The vasomotor domain score will be calculated as the all physical items ranging from 0 to 96, with lower scores indicating a better quality of life. |
at baseline, and weeks 4, 8, 20 and 32 | |
Secondary | Change From Baseline in the Sexual Functioning Domain of Menopause-Specific Quality of Life Questionnaire | The change from baseline in the sexual functioning domain of Menopause-Specific Quality of Life Questionnaire (MENQOL) at weeks 4, 8, 20 and 32 equals the sexual functioning domain of MENQOL at weeks 4, 8, 20 and 32 minus the sexual functioning domain of MENQOL at baseline, respectively. The sexual functioning domain contains 3 items (items 27-29). Each of the item scores ranges from 0 to 6. The vasomotor domain score will be calculated as the all sexual functioning items ranging from 0 to 18, with lower scores indicating a better quality of life. |
at baseline, and weeks 4, 8, 20 and 32 | |
Secondary | Change From Baseline in Serum FSH Level | The change from baseline in serum FSH level at weeks 8 and 20 equals FSH at weeks 8 and 20 minus FSH at baseline, respectively. | at baseline, and weeks 8 and 20 | |
Secondary | Change From Baseline in Serum E2 Level | The change from baseline in serum E2 level at weeks 8 and 20 equals E2 at weeks 8 and 20 minus E2 at baseline, respectively. | at baseline, and weeks 8 and 20 | |
Secondary | Change From Baseline in Serum LH Level | The change from baseline in serum LH level at weeks 8 and 20 equals LH at weeks 8 and 20 minus LH at baseline, respectively. | at baseline, and weeks 8 and 20 | |
Secondary | Change From Baseline in Serum FSH/LH Level | The change from baseline in serum FSH/LH at weeks 8 and 20 equals FSH/LH at weeks 8 and 20 minus FSH/LH at baseline, respectively. | at baseline, weeks 8 and 20 | |
Secondary | Number of Participants Who Used Other Treatment During Study | The number and percentage of patients who used other treatments will be compared between groups during weeks 1-8 and 9-32. | weeks 1-8; weeks 9-32 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01741974 -
Study of Anti-atherosclerotic and Estrogen-like Activity of Karinat in Perimenopausal Women
|
Phase 3 | |
Not yet recruiting |
NCT05522621 -
A Muticenter Clinical Study of Chinese Herbal Compound TJAOA102 in Alleviating Menopausal Syndrome
|
Early Phase 1 | |
Completed |
NCT01046643 -
Early Menopause Hormone Treatment and Cognition
|
N/A | |
Active, not recruiting |
NCT00694733 -
Regulation of Cortisol Metabolism and Fat Patterning
|
N/A | |
Completed |
NCT05759936 -
4-week Seaweed Supplementation on Menopause Symptoms and Psychological Wellbeing
|
N/A | |
Completed |
NCT05266079 -
Comparison Study for Perimenopausal Syndrome With Chinese Herbal Medicine
|
N/A | |
Completed |
NCT04520542 -
The Effect of Acupressure Application on Menopausal Symptoms
|
N/A | |
Completed |
NCT02749747 -
Sulpiride Versus Placebo for Reducting Hot Flushes During Climacteric
|
Phase 3 | |
Enrolling by invitation |
NCT03948269 -
The Effect of Internet- and Mobile-based Group Treatment in Menopausal Women
|
N/A | |
Recruiting |
NCT04031456 -
Autologous PRP Infusion May Restore Ovarian Function and May Promote Folliculogenesis in POI Patients
|
Phase 2/Phase 3 | |
Recruiting |
NCT02294500 -
Cohort Study to Evaluate Ovarian Function
|
N/A | |
Completed |
NCT02467673 -
Nanoparticulate Versus Micronized Steroids Delivery for Transdermal Hormone Replacement Therapy
|
Phase 2 | |
Recruiting |
NCT05280028 -
HRT on Overactive Bladder Symptoms, Sexual Function, Depressive Symptoms, Autonomic Function, and Arterial Stiffness
|
||
Completed |
NCT00289926 -
Efficacy and Safety of Oral DHEA Therapy for Postmenopausal Women on Sexual Function, Wellbeing and Vasomotor Symptoms
|
Phase 3 | |
Recruiting |
NCT01698164 -
Multi-centre Clinical Trial on Hormone Replacement Treatment in China
|
Phase 4 | |
Completed |
NCT05463081 -
Clinical Trial of "Magic Gyno" Laser Device
|
N/A | |
Completed |
NCT00933725 -
Efficacy and Safety of Traditional Chinese Medicine Intervention for Women With Menopausal Syndrome
|
Phase 3 | |
Enrolling by invitation |
NCT02001402 -
Chinese Health Investigation of Nurse Aging
|
N/A | |
Recruiting |
NCT04726254 -
The JULI Registry--Hemp and Cannabis Observational Registry
|
||
Completed |
NCT01931748 -
A Randomized, Double-Blind, Parallel, Non-Inferiority, Multicenter Trial Evaluate the Efficacy and Safety of UNCNT Compared to MELSMON in Female With Menopausal Syndrome
|
Phase 3 |